AbCellera to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Conference Participation: AbCellera announced its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in antibody drug development across endocrinology, women's health, immunology, and oncology.
- Investor Relations: The presentation will be accessible via a live audio webcast through a link on AbCellera's Investor Relations website, with a replay available post-presentation, aimed at enhancing communication and transparency with investors.
- Company Background: AbCellera is a clinical-stage biotechnology company focused on developing antibody-based medicines to address unmet needs in critical health areas, thereby increasing its influence in the biopharmaceutical industry.
- Information Access: Investors can find more details and updates regarding the conference on the company’s website, further enhancing its visibility and appeal in the capital markets.
ABCL.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ABCL
Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.560
Low
4.00
Averages
5.50
High
7.00
Current: 3.560
Low
4.00
Averages
5.50
High
7.00
Leerink
Outperform -> Market Perform
downgrade
$4
2025-11-07
Reason
Leerink
Price Target
$4
2025-11-07
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded AbCellera to Market Perform from Outperform with a $4 price target.
BMO Capital
Outperform
maintain
$5 -> $7
2025-08-08
Reason
BMO Capital
Price Target
$5 -> $7
2025-08-08
maintain
Outperform
Reason
BMO Capital raised the firm's price target on AbCellera to $7 from $5 and keeps an Outperform rating on the shares after its Q2 earnings beat. While previous quarters in recent memory have been more challenged for AbCellera as the company has attempted to transition to an internal development clinical biotechnology company, Q2 earnings highlighted positive updates with the addition of '688 as a new development candidate and initial clinical data for '635 expected in mid-2026, the analyst tells investors in a research note.
Leerink
Outperform
initiated
$5
2025-07-07
Reason
Leerink
Price Target
$5
2025-07-07
initiated
Outperform
Reason
Leerink assumed coverage of AbCellera with an Outperform rating and $5 price target. The firm likes AbCellera's pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.
Truist
Buy
downgrade
$28 -> $10
2025-05-16
Reason
Truist
Price Target
$28 -> $10
2025-05-16
downgrade
Buy
Reason
Truist lowered the firm's price target on AbCellera to $10 from $28 and keeps a Buy rating on the shares. The firm has updated its model after the company's Q1 results, though it continues to be positive about AbCellera, highlighting its continued execution of their wholly owned clinical pipeline, and given the company's hybrid business model with a focus shifting towards a clinical stage biotech, Truist is also updating its discount rate to reflect the transition, the analyst tells investors in a research note.
See All Ratings
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?